Child & Adolescent Psychopharmacology 2022

March 18, 2022 to March 20, 2022

The Zoom recordings will be available two weeks from the conclusion of the conference.

 

 

Why you should attend this year’s program – a message from Dr. Joseph Biederman

Complex challenges and evolving guidelines are changing the way you care for young psychiatric patients. These areas include new diagnostic criteria, patient-centered care models, new trends in substance abuse, research advances on genetics, and much more. It is more important than ever to find education that not only covers all these topics, but is also innovative, engaging, and empowers you to reach improved outcomes.

That's why it's critical to attend this hands-on, comprehensive conference. It provides psychiatrists, pediatricians, primary care and family practice physicians, nursing professionals, psychologists, social workers, and other mental health professionals with insights to optimize your assessment, treatment, and management of child and adolescent patients with psychiatric conditions.

  • Meet and engage face-to-face with renowned clinician-researchers who share the latest advances in their fields
  • Find guidance for complex signs and symptoms such as emotional outbursts, mood swings, and strange eating habits that can be indicative of psychiatric disorders yet can also be part of normal child development
  • Translate the latest research into optimal assessment and treatment strategies for anxiety, substance abuse, depression, eating disorders, OCD, psychosis, and much more

Conference will be held in Eastern Standard Time (EST).


Pricing

MDs/Doctoral-Level Professionals
Super Early Bird Registration (on or before February 12, 2022): $595.00
Early Bird Registration (February 13-March 4, 2022): $695.00
Regular Registration (after March 4, 2022): $795.00

Other Professionals or Trainees
Super Early Bird Registration (on or before February 12, 2022): $495.00
Early Bird Registration (February 13-March 4, 2022): $595.00
Regular Registration (after March 4, 2022): $695.00

SUNDAY ONLY (ADHD full day course)
MDs/Doctoral-Level Professionals: $345.00
Other Professionals or Trainees: $275.00

If you are interested in attending the Sunday ADHD sessions ONLY, you can register for them by clicking here. This is a full day program that concludes the Child & Adolescent Psychopharmacology conference.

Cancellation Policy

A refund minus a $100.00 administrative fee will be issued for refund requests received by February 25, 2022.  No refunds will be issued for refund requests made after February 25, 2022. Payments made may not be applied to future conferences or other educational activities.  There are no exceptions to these policies.


***The deeply discounted Super Early Bird Registration rate is NON-REFUNDABLE and NON-TRANSFERABLE and will not be refunded under any circumstances.

Syllabus

E-SYLLABUS
We provide all attendees  with completely free access to all slide presentations in digital PDF format prior to the conference. This is an environmentally friendly alternative and helps keep costs lower for all attendees. The e-syllabus will be available for 30 days after the conference. 
 


Massachusetts General Hospital Psychiatry Update & Board Preparation, 4th Edition

Board certification and recertification exams are critical career moments. That is why you should rely on the Massachusetts General Hospital Psychiatry Update & Board Preparation, Fourth Edition. It puts our 80+ years of clinical experience at your fingertips to help you prepare for your exam.

Purchase a print copy of our Board Preparation book here!


 

Target Audience

  • Psychiatrists
  • Primary care and family practice physicians
  • Pediatricians
  • Psychologists
  • Nursing professionals
  • Social workers
  • Residents
  • Other mental health, primary care and pediatric clinicians

Learning Objectives

  • Recognize the presentation, diagnosis, and current treatment options available for attention deficit and hyperactivity in childhood and adolescence.
  • Identify the presentation, diagnosis, and current treatment options available for behavioral problems and pervasive developmental disorders.
  • Discuss the presentation, diagnosis, and current treatment options available for depression, psychosis, manic depression, and anxiety.
  • Compare and contrast basic neuropharmacology, neuropsychologic testing data, psychopharmacologic properties of compounds, and the implications of psychiatric genetics for guiding day-to-day pediatric psychopharmacology treatment.
  • Recognize the risk management issues associated with adolescent substance use disorder and smoking, ethical and safe use of psychotropics, suicide risk and prevention, cardiovascular side effects and medical liability of stimulants, and liability prevention in psychopharmacology.
  • Review the comorbidity of ADHD with post-traumatic stress disorder and traumatic brain injury.
  • Explore emotional dysregulation, executive function and learning disorders in the context of ADHD.
  • Describe the relationship between antidepressants and suicide risk.
  • Discuss the available naturopathic treatments for emotional dysregulation in youth, including pros, cons, and available evidence.
  • Examine the evidence base for the Pediatric Autoimmune Neurological Disorder Associated with Streptococcus symptoms and its relation to OCD.
  • Describe the presentation, diagnosis, and current treatment options available for childhood onset schizophrenia.
  • Compare and contrast psychotherapeutic treatment approaches for children including DBT, CBT, and others.
  • Explore how animal models provide insight into child and adolescent psychiatric conditions, using ADHD as a model system.
  • Compare and contrast emotional dysregulation from mania, including presentation, course, and treatment.
  • Examine the relationship between learning disorders and ADHD.
  • Describe adult ADHD and discuss the controversies surrounding its diagnosis and treatment.
  • Examine the legal issues involved in treating individuals with ADHD and related disorders.
  • Describe the problems associated with treatment non-adherence and provide strategies to improve adherence in the clinical setting.
Course summary
Available credit: 
  • 17.50 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

    McLean Hospital designates this Live activity for a maximum of 17.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

  • 17.50 Nursing Contact Hours

    Massachusetts General Laws, Chapter 13, sections 13, 14, 14A, 15 and 15D and Chapter 112, sections 74 through 81C authorize the Board of Registration in Nursing to regulate nursing practice and education.

    This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 17.50 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

  • 17.50 Social Workers

    The Collaborative of NASW, Boston College, and Simmons College Schools of Social Work authorizes social work continuing education credits for courses, workshops, and educational programs that meet the criteria outlined in 258 CMR of the Massachusetts Board of Registration of Social Workers

    This program has been approved for 17.50 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 90787-2

  • 17.50 Participation

    This course allows other providers to claim a Participation Certificate upon successful completion of this course.

    Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credit™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credit™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

  • 17.50 Psychologists CE Credit

    The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.

    This offering meets the criteria for 17.50 Continuing Education (CE) credits per presentation for psychologists.

Registration opens: 
07/01/2021
Course closes: 
09/24/2022
Event starts: 
03/18/2022 - 7:45am EDT
Event ends: 
03/20/2022 - 4:40pm EDT
Cost:
$795.00
Rating: 
0

Child and Adolescent Psychopharmacology

March 18-20, 2022

PROGRAM AGENDA

 

FRIDAY, MARCH 18, 2022

 

8:00 – 8:10 AM            Introduction
Joseph Biederman, MD

 

MODULE TOPIC: OVERVIEW OF PEDIATRIC PSYCHOPHARMACOLOGY

8:10 – 8:30 AM            Diagnosis & Assessment in Pediatric Psychopharmacology
Joseph Biederman, MD

8:30 – 8:50 AM            Implications of Psychiatric Genetics for Psychopharmacology
Stephen V. Faraone, PhD

8:50 – 9:10 AM            Question & Answer Panel
Moderator: Timothy E. Wilens, MD
Panelists: Joseph Biederman, MD & Stephen V. Faraone, PhD

 

MODULE TOPIC: ADHD AND SUBSTANCE USE DISORDERS

9:10 – 10:00 AM           ADHD and its Treatment Across the Life Cycle
Joseph Biederman, MD

10:00 – 10:20 AM         Substance Use Disorders: Part I
Timothy E. Wilens, MD

10:20 – 10:40 AM         Substance Use Disorders: Part II
Timothy E. Wilens, MD

10:40 – 11:10 PM         Question & Answer Panel
Moderator: David H. Rubin, MD
Panelists: Joseph Biederman, MD & Timothy E. Wilens, MD

11:10 – 12:10 PM         Break

 

 MODULE TOPIC: MOOD DISORDERS AND EMOTIONAL DYSREGULATION

12:10 – 12:30 PM         Juvenile Depression
David H. Rubin, MD

12:30 – 12:50 PM         Illuminating the Black Box: Antidepressants, Youth and Suicide
David H. Rubin, MD

12:50 – 1:10 PM           Juvenile Mania
Janet Wozniak, MD

1:10 – 1:30 PM             Differentiating Unipolar vs. Bipolar Mood Disorders in the Young
Janet Wozniak, MD

1:30 – 1:50 PM             Schizophrenia & Pharmacological Approaches to Pediatric Mania
Janet Wozniak, MD

1:50 – 2:05 PM             Break  

2:05 – 2:25 PM             Distinguishing Emotional Dysregulation from Mania
Joseph Biederman, MD

2:25 – 2:55 PM             Question & Answer Panel
Moderator: Timothy E. Wilens, MD
Panelists: Joseph Biederman, MD, Janet Wozniak, MD & David H. Rubin, MD

2:55 – 3:55 PM             Ask the Experts
Moderator: David H. Rubin, MD
Joseph Biederman, MD, Timothy E. Wilens, MD, Janet Wozniak, MD

3:55 PM                       Adjourn

 

SATURDAY, MARCH 19, 2022

 

8:00 – 8:05 AM            Introduction
Joseph Biederman, MD

MODULE TOPIC: OCD, ANXIETY DISORDERS, TOURETTE’S, PANDAS AND ASD TRAITS

8:05 – 8:25 AM            Obsessive Compulsive Disorder
Erica Greenberg, MD

8:25 – 8:45 PM             Pediatric Anxiety Disorders
Erica Greenberg, MD

8:45 – 9:05 AM            Tourette’s Disorder & Tics
Erica Greenberg, MD

9:05 – 9:25 AM            PANDAS
Erica Greenberg, MD

9:25 – 9:45 AM            Are Autistic Traits Clinically Meaningful?
Joseph Biederman, MD

9:45 – 10:15 AM           Question & Answer Panel
Moderator: Joseph Biederman, MD
Panelist: Erica Greenberg, MD

10:15 – 10:30 AM         Break

 

MODULE TOPIC: PSYCHOLOGICAL ASSESSMENT & INTERVENTION

10:30 – 10:50 AM         Cognitive Behavioral Treatment for Young Adults: Education & Psychological Testing
Aude Henin, PhD

10:50 – 11:10 AM         Cognitive Behavioral Therapy for Anxiety in Young Children
Aude Henin, PhD

11:10 – 11:30 PM         Using Psychological Assessment to Inform Treatment
Aude Henin, PhD

11:30 – 12:00 PM         Question & Answer Panel
Moderator: Joseph Biederman, MD
Panelists: Erica Greenberg, MD, Aude Henin, PhD

12:00 PM                     Adjourn

 

SUNDAY, MARCH 20, 2022 ADHD DAY

 

8:00 – 8:05 AM            Introduction
Joseph Biederman, MD, Timothy E. Wilens, MD

 

MODULE TOPIC: DIAGNOSIS AND UNDERPINNINGS OF ADHD

8:05 – 8:25 AM            Definitions and Overview of ADHD
Joseph Biederman, MD

8:25 – 8:45 AM            Genetics of ADHD
Stephen V. Faraone, PhD

8:45 – 9:05 AM            Neuroimaging and ADHD
Susan Whitefield-Gabrieli, PhD

9:05 – 9:25 AM            Diagnosis of Adult ADHD
Joseph Biederman, MD

9:25 – 9:55 AM            Question & Answer Panel
Moderator: Timothy E. Wilens, MD
Panelists: Stephen V. Faraone, PhD, Joseph Biederman, MD, Susan Whitefield-Gabrieli, PhD, Thomas Spencer, MD

9:55 – 10:10 AM           Break

MODULE TOPIC: TREATMENT OF ADHD

10:10 – 10:30 AM         Treatment of ADHD with Stimulants I Pediatrics
Thomas Spencer, MD

10:30 – 10:50 AM         Treatment of ADHD with Stimulants II Adults
Thomas Spencer, MD

10:50 – 11:10 AM         Pharmacological Treatment of ADHD Across the Life Span: Nonstimulants
Timothy E. Wilens, MD

11:10 -11:30 AM          The Serious Problem of Non-Adherence to Treatment in ADHD and Ways to Mitigate it
Joseph Biederman, MD

11:30 – 12:00 PM         Question & Answer Panel
Moderator: Stephen V. Faraone, PhD
Panelists: Joseph Biederman, MD, Timothy E. Wilens, MD, Thomas Spencer, MD

12:00 – 1:00 PM           Break  

MODULE TOPIC: EMOTIONAL DYSREGULATION, EXECUTIVE FUNCTION AND LEARNING DISORDERS

1:00 – 1:20 PM             CBT & Psychosocial Treatments in ADHD
Aude Henin, PhD

1:20 – 1:40 PM             ADHD & Education
Aude Henin, PhD

1:40 – 2:00 PM            Functional Outcomes in ADHD and the Critical Importance of Treatment to Mitigate Them
Joseph Biederman, MD

2:00 – 2:30 PM             Question & Answer Panel
Moderator: Timothy E. Wilens, MD
Panelists: Joseph Biederman, MD & Aude Henin, PhD

2:30 – 2:45 PM             Break

MODULE TOPIC: ADDRESSING COMORBIDITIES OF ADHD

2:45 – 3:05 PM             ADHD, Tics and Tourette’s Disorder
Erica Greenberg, MD

3:05 – 3:25 PM             Comorbidity of ADHD with Substance Use Disorders and Associated Risk Management Issues
Timothy E. Wilens, MD

3:25 – 3:45 PM             Management of ADHD in the Context of Autism Spectrum Disorders
Joseph Biederman, MD

3:45 – 4:05 PM             ADHD, PTSD & TBI
Joseph Biederman, MD

4:05 – 4:35 PM             Question & Answer Panel
Moderator: Joseph Biederman, MD
Panelists: Erica Greenberg, MD, & Timothy E. Wilens, MD

4:35 PM                       Adjourn

Course Director(s)

Joseph Biederman, MD

has a financial relationship (Professional Services) with Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire/Takeda, Sunovion, and Theravance;.
has a financial relationship (Financial Support) with Tris;.
has a financial relationship (Financial Support) with Genentech, Headspace Inc., Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., and Tris;.
has a financial relationship (Professional Services) with MEMOTEXT;.

David Rubin, MD

has no relevant financial relationships to disclose at this time.

Thomas Spencer, MD

has a financial relationship (Patent) with US patent (#61/233,686);.
has a financial relationship (Professional Services) with Avekshan;.
has a financial relationship (Patent) with US patent (#61/233,686);.
has a financial relationship (Financial Support) with ADHD Scales Royalty Licensing ;.
has a financial relationship (Professional Services) with The FDA; Department of Defense ;.
Planner(s)

Joseph Biederman, MD

has a financial relationship (Professional Services) with Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire/Takeda, Sunovion, and Theravance;.
has a financial relationship (Financial Support) with Tris;.
has a financial relationship (Financial Support) with Genentech, Headspace Inc., Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., and Tris;.
has a financial relationship (Professional Services) with MEMOTEXT;.

Jane Pimental, MPH

has no relevant financial relationships to disclose at this time.

David Rubin, MD

has no relevant financial relationships to disclose at this time.

Thomas Spencer, MD

has a financial relationship (Patent) with US patent (#61/233,686);.
has a financial relationship (Financial Support) with ADHD Scales Royalty Licensing ;.
has a financial relationship (Professional Services) with The FDA; Department of Defense ;.
has a financial relationship (Professional Services) with Avekshan;.
has a financial relationship (Patent) with US patent (#61/233,686);.

Susan,Ph.D. Sprich, Ph.D.

has a financial relationship (Other) with Springer;.
has a financial relationship (Other) with Oxford University Press;.
has a financial relationship (Other) with Association for Behavioral and Cognitive Therapies (ABCT);.
Speaker(s)

Joseph Biederman, MD

has a financial relationship (Professional Services) with Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire/Takeda, Sunovion, and Theravance;.
has a financial relationship (Financial Support) with Tris;.
has a financial relationship (Financial Support) with Genentech, Headspace Inc., Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., and Tris;.
has a financial relationship (Professional Services) with MEMOTEXT;.

Stephen Faraone, PhD

has a financial relationship (Financial Support) with Elsevier, Guilford Press, Oxford University Press ;.
has a financial relationship (Grant Or Contract) with Shire/Takeda;.
has a financial relationship (Grant Or Contract) with Supernus;.
has a financial relationship (Professional Services) with Genomind;.
has a financial relationship (Grant Or Contract) with Sunovion;.
has a financial relationship (Professional Services) with Arbor, Ondosis, KemPharm/Corium;.
has a financial relationship (Grant Or Contract) with Otsuka;.
has a financial relationship (Professional Services) with Akili Interactive Labs, Aardvark, Aveksham, Enzymotec, Ironshore, Noven, Rhodes, Tris, and Vallon;.

Erica Greenberg, MD

has a financial relationship (Professional Services) with Tourette Association of America ;.
has a financial relationship (Professional Services) with MGH Psychiatry Academy, Psychiatry Education Forum;.

Aude,Ph.D. Henin, PhD

has a financial relationship (Professional Services) with Oxford University Press;.
has a financial relationship (Professional Services) with Clintara, Alkermes;.

David Rubin, MD

has no relevant financial relationships to disclose at this time.

Thomas Spencer, MD

has a financial relationship (Financial Support) with ADHD Scales Royalty Licensing ;.
has a financial relationship (Professional Services) with The FDA; Department of Defense ;.
has a financial relationship (Professional Services) with Avekshan;.
has a financial relationship (Patent) with US patent (#61/233,686);.
has a financial relationship (Patent) with US patent (#61/233,686);.

Susan Whitfield-Gabrieli

has no relevant financial relationships to disclose at this time.

Janet,M.D. Wozniak, MD

has a financial relationship (Financial Support) with Bantam Books;.
has a financial relationship (Financial Support) with Johnson and Johnson; Pfizer ;.
has a financial relationship (Professional Services) with Emalex; Noctrix; CVS;.

THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY 2022 AND HAS APPROVED THIS PROGRAM AS A PART OF A COMPREHENSIVE CONTINUING MEDICAL EDUCATION ACTIVITY, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF CONTINUING CERTIFICATION.

This program is approved as an ABPN-Approved CME activity. It awards up to 17.50 Category 1 CME credits.


AMERICAN ACADEMY OF FAMILY PHYSICAINS (AAFP)

AAFP has approved Child and Adolescent Psychopharmacology and deemed it acceptable for up to 17.50 credits.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Available Credit

  • 17.50 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

    McLean Hospital designates this Live activity for a maximum of 17.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

  • 17.50 Nursing Contact Hours

    Massachusetts General Laws, Chapter 13, sections 13, 14, 14A, 15 and 15D and Chapter 112, sections 74 through 81C authorize the Board of Registration in Nursing to regulate nursing practice and education.

    This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 17.50 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

  • 17.50 Social Workers

    The Collaborative of NASW, Boston College, and Simmons College Schools of Social Work authorizes social work continuing education credits for courses, workshops, and educational programs that meet the criteria outlined in 258 CMR of the Massachusetts Board of Registration of Social Workers

    This program has been approved for 17.50 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 90787-2

  • 17.50 Participation

    This course allows other providers to claim a Participation Certificate upon successful completion of this course.

    Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credit™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credit™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

  • 17.50 Psychologists CE Credit

    The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.

    This offering meets the criteria for 17.50 Continuing Education (CE) credits per presentation for psychologists.

Price

Cost:
$795.00
Please login or register to take this course.

Course Director

Joseph Biederman MD
Thomas J. Spencer, MD
Timothy E. Wilens
David H. Rubin, MD

Planners

Joseph Biederman MD
Thomas J. Spencer, MD
Timothy E. Wilens
David H. Rubin, MD
Jane Pimental, MPH
Susan E. Sprich, PhD, psychologist reviewer

ARCHIVED DISCLOSURES

Disclosure Information

In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:              

Commercial Interest

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial relationships

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.  Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.  ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant financial relationships 

ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant.  Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:

Susan Sprich, PhD
Royalties (Co-Author): Oxford University Press
Royalties (Co-Edited Book): Springer
Honoraria (Associate Editors): Association for Behavioral and Cognitive Therapies (ABCT)

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.


Disclosure Information 

In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all financial relationships with ineligible companies for the past 24 months, as defined below:                        

Ineligible Companies 

The ACCME defines an “Ineligible company” as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”  For more information, visit

accme.org/standards

Financial Relationships

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.  Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. 

Mitigation of Financial Relationships

All financial relationships are reviewed to determine which ones are relevant, and then measures are taken to mitigate all relevant financial relationships and ensure that they do not insert commercial bias into the content of the education.   

The following planners, speakers, content reviewers, and others in control of educational content have reported financial relationships with ineligible companies over the past 24 months. Measures have been taken to mitigate the impact of these financial relationships on the educational content and ensure that they do not insert commercial bias into the content of this education.        

Joseph Biederman, MD
Royalties (ADHD Diagnosis): Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire/Takeda, Sunovion, and Theravance

Partnership( commercialize a digital health intervention to improve adherence in ADHD): MEMOTEXT

Research Support: Genentech, Headspace Inc., Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., and Tris

Honorarium (Scientific Presentation): Tris

Stephen Faraone, PhD
Research Grants/CME Grant Support/Consulting: Otsuka

Research Grants/CME Grant Support: Sunovion

Research Grants/Advisory Board: Supernus

CME Grant Support: Shire/Takeda

Consulting: Akili Interactive Labs, Aardvark, Aveksham, Enzymotec, Ironshore, Noven, Rhodes, Tris, and Vallon

Consulting/Advisory Board: Arbor, Ondosis, KemPharm/Corium

Consulting/Advisory Board/Stock: Genomind

US Patent: A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD

Royalties: Elsevier, Guilford Press, Oxford University Press         

Erica Greenberg, MD
Speaker: MGH Psychiatry Academy, Psychiatry Education Forum

Speaker (Advisory Board): Tourette Association of America    

Aude Henin, PhD
Royalties: Oxford University Press

Consultation: Clintara, Alkermes

Thomas Spencer, MD

Consultant (MGH Advisor): Avekshan

Research Support(MGH PI): The FDA; Department of Defense
Royalties (MGH Corporate Sponsored): ADHD Scales Royalty Licensing

Non-Stimulant Treatment for ADHD (no license fees): US patent (#61/233,686)

Stimulant Abuse Prevention (no license fees): US patent (#61/233,686)

Timothy E. Wilens, MD

Principal Investigator (Grant/Research Support): NIH (NIDA)

Consultant: Arbor Pharmaceuticals; Otsuka; KemPharm; Ironshore; Vallon

Intellectual Property (Licensing Agreement): Ironshore

Intellectual Property (Published book): Guilford Press

Intellectual Property (Co/edited textbook): Cambridge University Press

Clinical Consulting: Gavin Foundation; Bay Cove Human Services; US National Football League (ERM Associates); US Minor/Major League Baseball

Consultant (Shared IP): White Rhino/3D

Janet Wozniak, MD

Research Support: Johnson and Johnson; Pfizer

Author: Bantam Books

Consultation Fees (Spouse): Emalex; Noctrix; CVS

 

All other individuals in a position to control the content of this educational activity have reported no financial relationships with ineligible companies.


Hardware/Software Specifications

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration

Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit


Privacy Policy

Please click here to review our privacy policy.